ofloxacin has been researched along with Pulmonary Disease, Chronic Obstructive in 30 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to determine the intrapulmonary profile of high-dose (750 mg) levofloxacin in patients during an acute exacerbation of chronic bronchitis (AECB)." | 9.16 | Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ( Baughman, RP; Nicolau, DP; Sutherland, C; Winget, D, 2012) |
| "Levofloxacin was measured using a high-performance liquid chromatographic tandem mass spectrometric (HPLC/MS/MS) technique." | 5.34 | Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ( Conte, JE; Golden, JA; Little, E; McIver, M; Zurlinden, E, 2007) |
| " The purpose of this study was to determine the intrapulmonary profile of high-dose (750 mg) levofloxacin in patients during an acute exacerbation of chronic bronchitis (AECB)." | 5.16 | Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. ( Baughman, RP; Nicolau, DP; Sutherland, C; Winget, D, 2012) |
| "A 72-year-old female dialysis patient with insulin-dependent diabetes mellitus who was under long-term medication with oral prednisolone due to chronic obstructive pulmonary disease was given levofloxacin for one week to treat an acute bronchitis (one 500 mg dose on the first day, 125 mg/day orally from second day onwards)." | 3.74 | [Fluoroquinolone-induced Achilles tendon rupture]. ( Maurin, N, 2008) |
| "Patients with AECOPD and without radiographic evidence of pneumonia were enrolled and randomized to either levofloxacin 500 mg daily or cefuroxime 250 mg twice daily in the mildmoderate exacerbation group, or 500 mg twice daily in the severe exacerbation group, for seven days." | 2.78 | Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease. ( Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, JH; Lee, SM; Park, GM; Yim, JJ; Yoo, CG; Yoon, HI, 2013) |
| "Treatment with ofloxacin significantly reduced the need for additional courses of antibiotics (28." | 2.70 | Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. ( Abroug, F; Belghith, M; Besbes, L; Elatrous, S; Marghli, S; Nouira, S, 2001) |
| "Levofloxacin was measured using a high-performance liquid chromatographic tandem mass spectrometric (HPLC/MS/MS) technique." | 1.34 | Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease. ( Conte, JE; Golden, JA; Little, E; McIver, M; Zurlinden, E, 2007) |
| "Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment." | 1.33 | In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. ( Ercibengoa, M; González, A; Larruskain, J; Marimón, JM; Pérez-Trallero, E, 2005) |
| "Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) are mild-to-life-threatening adverse reactions that have been described after exposure to fluoroquinolones." | 1.31 | Levofloxacin-induced toxic epidermal necrolysis in an elderly patient. ( Ackerman, BH; Cawley, MJ; Digwood-Lettieri, S; Guilday, RJ; Haith, LR; Patton, ML; Reilly, KJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (73.33) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Astaf'ev, AV | 1 |
| Styrt, EA | 1 |
| Sinopal'nikov, AI | 1 |
| Schuster, S | 1 |
| Diethelm, M | 1 |
| Yoon, HI | 1 |
| Lee, CH | 1 |
| Kim, DK | 1 |
| Park, GM | 1 |
| Lee, SM | 1 |
| Yim, JJ | 1 |
| Kim, JY | 1 |
| Lee, JH | 1 |
| Lee, CT | 1 |
| Chung, HS | 1 |
| Kim, YW | 1 |
| Han, SK | 1 |
| Yoo, CG | 1 |
| Blasi, F | 1 |
| Zeineh, NS | 1 |
| Guchev, IA | 1 |
| Melekhina, EV | 1 |
| Iudenich, OV | 1 |
| Nicolau, DP | 1 |
| Sutherland, C | 1 |
| Winget, D | 1 |
| Baughman, RP | 1 |
| Aaron, SD | 1 |
| Vandemheen, KL | 1 |
| Maltais, F | 1 |
| Field, SK | 1 |
| Sin, DD | 1 |
| Bourbeau, J | 1 |
| Marciniuk, DD | 1 |
| FitzGerald, JM | 1 |
| Nair, P | 1 |
| Mallick, R | 1 |
| Roig, J | 1 |
| Martínez Benazet, J | 1 |
| Casal, J | 1 |
| Malcolm, C | 1 |
| Marrie, TJ | 1 |
| Melhus, A | 1 |
| Apelqvist, J | 1 |
| Larsson, J | 1 |
| Eneroth, M | 1 |
| Miravitlles, M | 1 |
| Torres, A | 1 |
| Lode, H | 1 |
| Eller, J | 1 |
| Linnhoff, A | 1 |
| Ioanas, M | 1 |
| Shmelev, EI | 1 |
| Pérez-Trallero, E | 1 |
| Marimón, JM | 1 |
| González, A | 1 |
| Ercibengoa, M | 1 |
| Larruskain, J | 1 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Sánchez Muñoz, LA | 1 |
| Sanjuán Portugal, FJ | 1 |
| Naya Machado, J | 1 |
| Castiella Herrero, J | 1 |
| Carranza González, R | 1 |
| Tena Gómez, D | 1 |
| Prieto Gómez, E | 1 |
| Barberá Farré, JR | 1 |
| Fernández Cenjor, J | 1 |
| Ruiz-González, A | 1 |
| Giménez, A | 1 |
| Gómez-Arbonés, X | 1 |
| Soler-González, J | 1 |
| Sánchez, V | 1 |
| Falguera, M | 1 |
| Porcel, JM | 1 |
| Petitpretz, P | 1 |
| Choné, C | 1 |
| Trémolières, F | 1 |
| Conte, JE | 1 |
| Golden, JA | 1 |
| McIver, M | 1 |
| Little, E | 1 |
| Zurlinden, E | 1 |
| Parmar, C | 1 |
| Meda, KP | 1 |
| Maurin, N | 1 |
| Habib, MP | 1 |
| Nuño Mateo, FJ | 1 |
| Noval Menéndez, J | 1 |
| Suárez, M | 1 |
| Guinea, O | 1 |
| Karim, A | 1 |
| Ahmed, S | 1 |
| Rossoff, LJ | 1 |
| Siddiqui, RK | 1 |
| Steinberg, HN | 1 |
| Nouira, S | 1 |
| Marghli, S | 1 |
| Belghith, M | 1 |
| Besbes, L | 1 |
| Elatrous, S | 1 |
| Abroug, F | 1 |
| Digwood-Lettieri, S | 1 |
| Reilly, KJ | 1 |
| Haith, LR | 1 |
| Patton, ML | 1 |
| Guilday, RJ | 1 |
| Cawley, MJ | 1 |
| Ackerman, BH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TNF-alpha Antagonists for Acute Exacerbations of COPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial[NCT00789997] | Phase 2/Phase 3 | 81 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"FEV1 was obtained using calibrated spirometers at approximately the same time of day at all visits throughout the study. The highest acceptable FEV1 and the highest FVC measurement each obtained on any of three blows (even if not from the same curve) meeting the American Thoracic Society criteria constituted the data for that test set.~Not all participants had Day 14 FEV1 measures collected" (NCT00789997)
Timeframe: Day 0 to Day 14
| Intervention | percentage of change in FEV1 (Mean) |
|---|---|
| Etanercept | 15.2 |
| Prednisone | 20.1 |
In the etanercept group 16/40 (40%) failed treatment compared with 12/38 (32%) in the prednisone group. (NCT00789997)
Timeframe: Day 0 to Day 90
| Intervention | participants (Number) |
|---|---|
| Etanercept | 16 |
| Prednisone | 12 |
4 reviews available for ofloxacin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
[Therapeutic experience with levofloxacin in pneumonia and COPD].
Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross In | 2009 |
[Respiratory fluoroquinolones in the treatment of exacerbations of chronic obstructive lung disease].
Topics: Administration, Oral; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteria; Cefepime; Cep | 2004 |
Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature.
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Casts, Surgical; Female; Fol | 2007 |
Management of clinical failures in non-ICU patients with chronic obstructive pulmonary disease exacerbations.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Bronchiectasis; Humans; Male; Ofloxacin; Pulmonary D | 2001 |
8 trials available for ofloxacin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
[Infectious exacerbation of chronic obstructive pulmonary disease: prospects for high-dose levofloxacin therapy].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Female; Humans; Levoflox | 2013 |
Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease.
Topics: Aged; Anti-Bacterial Agents; Bacteria; Cefuroxime; Dose-Response Relationship, Drug; Drug Monitoring | 2013 |
Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; | 2012 |
TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Double-Blind Method; Etanercept; | 2013 |
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Disease Pr | 2004 |
Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease.
Topics: Amoxicillin; Anti-Infective Agents; Cefuroxime; Clarithromycin; Female; Follow-Up Studies; Forced Ex | 2007 |
Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval.
Topics: Aged; Bronchitis, Chronic; Cefuroxime; Female; Heart Failure; Humans; Levofloxacin; Male; Middle Age | 2007 |
Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Double-Blind Method; Female; Hospital Mortality; | 2001 |
18 other studies available for ofloxacin and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
[Achilles heel of COPD].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Diagnosis, Di | 2013 |
A toxic combination.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Drug Therapy, Combination; Electroc | 2010 |
[Levofloxacin. expediency of high-dose regimens in therapy of lower respiratory tract infections].
Topics: Community-Acquired Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; | 2011 |
[The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?].
Topics: Anti-Infective Agents; Humans; Levofloxacin; Ofloxacin; Pulmonary Disease, Chronic Obstructive; Resp | 2002 |
[Fluoroquinolone superior to macrolide. Longer infection free period after acute bronchitis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Bronchitis; Clarithromycin; Doub | 2003 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azit | 2003 |
Levofloxacin-associated Achilles tendon rupture and tendinopathy.
Topics: Achilles Tendon; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Humans; Levofloxacin; Male; | 2003 |
[Equally whether the child's lung or chronically inflamed bronchi. Acute bacterial infections have to be terminated fast].
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; B | 2004 |
Antibiotics in exacerbations of COPD: lessons from the past.
Topics: Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Disease Progression; Humans; Ofloxacin; | 2004 |
In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophor | 2005 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
[Levofloxacin-induced tendon rupture with fatal outcome].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Comorbidity; Fatal Outcome; Humans; Levofloxacin; Male | 2006 |
[Pneumonia by Corynebacterium pseudodiphteriticum: an infection to consider].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Corynebacte | 2006 |
Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
Topics: Adult; Aged; Area Under Curve; Blood Chemical Analysis; Bronchitis, Chronic; Bronchoalveolar Lavage | 2007 |
[Fluoroquinolone-induced Achilles tendon rupture].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Bronchitis; Diabetes Mellitus, Type 1; Female; Humans; | 2008 |
[Achilles pain and functional impotence in a patient with chronic obstructive pulmonary disease with pneumonia. Tendon rupture caused by levofloxacin].
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Humans; Levofloxacin; Male; Ofloxacin; Pain; Pneumonia | 2001 |
Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease.
Topics: Acute Disease; Aged; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Female; Humans; | 2001 |
Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Fluid Therapy; Humans; Levofloxa | 2002 |